cg0070,pembrolizumab
cg oncology,merck
['pembro', 'cg0070', 'calm']
right now , is presenting results of phase 2, single arm study of cg0070 combined with pembrolizumab in patients with (nmibc) unresponsive to bacillus calmette-guerin (bcg). stop by room 258abc #sitc22 